Anti‐angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis

Abstract

Although anti‐angiogenic therapies (AATs) have some effects against multiple malignancies, they are limited by subsequent tumor vasculogenesis and progression. To investigate the mechanisms by which tumor vasculogenesis and progression following AATs, we transfected microRNA (miR)‐9 into human umbilical vein endothelial cells (HUVECs) to mimic the tumor‐associated endothelial cells in hepatocellular carcinoma and simulated the AATs in vitro and in vivo. We found that administration of the angiogenesis inhibitor vandetanib completely abolished miR‐9‐induced angiogenesis and promoted autophagy in HUVECs, but induced the release of vascular endothelial growth factor (VEGF)‐enriched exosomes. These VEGF‐enriched exosomes significantly promoted the formation of endothelial vessels and vasculogenic mimicry in hepatocellular carcinoma and its progression in mice. Anti‐autophagic therapy is proposed to improve the efficacy of AATs. However, similar effects by AATs were observed with the application of anti‐autophagy by 3‐methyladenine. Our results revealed that tumor vasculogenesis and progression after AATs and anti‐autophagic therapies were due to the cross‐talk between endothelial cells and tumor cells via VEGF‐enriched exosomes. These findings provide a critical insight into a new interpretation of why AATs have not achieved expected outcomes. They also suggest that control of exosome release or alteration of exosome cargo composition to inhibit tumor vasculogenesis may augment the anti‐angiogenic and anti‐autophagic therapies for tumors. Support or Funding Information Supported by National Natural Science Foundation of China (Grant no.11402153). This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

The diagnosis values of serum STAT4 and sEng in preeclampsia

“…The disorder of disk spiral artery remodeling causes low placental perfusion, ischemic anoxia, and abnormal placental function . The placenta syntheses and releases a variety of inflammatory mediators and vasoactive factors such as STAT4, sFlt‐l, sEng, TNF‐alpha, and IL‐6, which act on vascular endothelial cells, and the dysfunction of endothelial cells might cause pathological process such as tumorigenesis . The elevated levels of circulating endothelin (ET‐1) and reactive oxygen species (ROS), as well as increased sensitivity to angiotensin II, lead to multiple organ dysfunction .…”

Protective effect of anisodamine hydrobromide on lipopolysaccharide-induced acute kidney injury

“…Anisodamine might play a significant role in LPS-induced microvascular endothelial cells [27]. Endothelial cells interact with other cells via exosome [28]. Anisodamine acts as a cholinergic antagonist to improve smooth muscle function [29].…”

Important players in carcinogenesis as potential targets in cancer therapy: an update

“…The described mechanism combining the effect of exosomes with the effects caused by neutrophils is not the only one by which cell vesicles are involved in the particular stages of tumor development. By directly supplying factors such as VEGF [146,147] EGFR [148] fibroblast growth factor (FGF) [149] or angiopoietin [150] they contribute to new blood vessels development that ensures the optimal growth environment for the dividing cells. The indirect pro-angiogenic activity is the transport of miR-210 through exosomes secreted by tumor cells [151,152].…”